Novartis Oncology launches a new mTOR Web site

The science of mTOR and its clinical implications are subjects of evolving understanding among the medical community. will serve as a valuable resource to those who wish to learn more about the role of mTOR in cancer treatment. The site content includes a guide which explains how mTOR works in different diseases, including Renal Cell Carcinoma and Neuroendocrine Tumors. These are two types of cancer in which clinical trials are underway. The site features an animated, three-dimensional illustration depicting how mTOR works in cell metabolism, growth, proliferation, and angiogenesis. Site visitors can access downloadable brochures, a glossary of terms, clinical trial information, and recent publications on mTOR. In addition, visitors can sign up for a regular eNewsletter. Novartis Oncology plans to update the site on an ongoing basis, as new information and resources become available. To view this website, visit
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

ConclusionsThe results pointed out that the high expression of miR-106b-5p serves as an independent factor for predicting the worse prognosis of RCC patients.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Michael Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology, Georgetown University Medical Center, Discusses KEYNOTE 42... Author: obr Added: 03/20/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
We report a case of ureteral stump carcinoma following a radical nephrectomy for renal cell carcinoma. A 76-year-old man was diagnosed as having ascending colon cancer and a right renal carcinoma. He was treated with partial colon resection and radical nephrectomy without lymphadenectomy. The histology was renal cell carcinoma. Three years after that surgery, he complained of intermittent macrohematuria. Abdominal computed tomography (CT) suggested a solid mass in the pelvis. We then performed a biopsy with CT guidance. An epithelial tumor was suspected by immunohistochemistry. A total excision of ureter was then performed...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Authors: Naito S, Ichiyanagi O, Ito H, Kabasawa T, Kanno H, Narisawa T, Fukuhara H, Yagi M, Kurota Y, Yamagishi A, Sakurai T, Nishida H, Kawazoe H, Yamanobe T, Kato T, Makhov P, Kolenko VM, Yamakawa M, Tsuchiya N Abstract Eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) is phosphorylated and activated by mammalian target of rapamycin complex 1, which serves as a regulator of cell growth, cell survival, metastasis and angiogenesis in many types of cancer. The aim of this study was to evaluate the role of phosphorylated 4EBP1 (p4EBP1) in primary renal cell carcinoma (RCC) as a biomarker in metast...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, the present study demonstrated that Wnt10a may have an oncogenic role during carcinogenesis of CRC through activation of Wnt/β-catenin signaling. PMID: 30881490 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In this article, Dr. Marc-Oliver Grimm provides an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session.03/18/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
AbstractBackgroundSerum protein fraction (SPF) is a common parameter reflecting the nutritional and inflammatory status of the human body. However, its role in patients with cancer, particularly those treated with targeted agents, is unknown.ObjectiveWe conducted this study to explore the prognostic value of SPF in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors and its association with clinical characteristics.MethodsPatients with mRCC (n = 213) who initiated first-line sunitinib or sorafenib systemic therapy for metastatic disease between March 2007 and June 2017...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
AbstractPancreatectomy might confer a survival benefit in patients with metastatic tumors of the pancreas (MTPs); however, the optimal treatment for MTP has not been established. We reviewed six patients with MTP undergoing pancreatectomy and discussed the clinical features, surgical treatment, and survival. The sites of primary cancer included renal cell carcinoma (RCC) (n = 5; 83.3%) and rectal cancer (n = 1; 16.7%). The median interval between the resection of the primary site and the development of MTP was 157 months (range, 16–180 months). Three (60.0%) of the five cases of ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionProper differentiation of RCCs related to translocation of MiT family requires immunostaining for TFE3, especially in the case of younger patients, among which the prevalence of this genetic mutation is frequent.
Source: Journal of Pediatric Surgery Case Reports - Category: Surgery Source Type: research
Authors: Wei R, Ye X, Zhao Y, Jia N, Liu T, Lian W, Wei H, Zhang G, Song L Abstract MicroRNAs (miRs) have emerged as critical modulators of tumor initiation and progression in numerous types of human cancer, including clear cell renal cell carcinoma (ccRCC), which is the most common subtype of renal cell carcinoma. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a newly characterized oncoprotein and its overexpression has been reported to promote cellular epithelial-mesenchymal transition and the tumor progression of ccRCC. The present study examined the effects of miR-218 on CIP2A expression in ccRCC cell...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Learning | Neurology | Neuroscience | Renal Cell Carcinoma | Science | Universities & Medical Training | Urology & Nephrology | Websites